Sage Therapeutic Shares Owned By Insiders vs. Revenue

SAGE Stock  USD 5.61  0.61  12.20%   
Based on the measurements of profitability obtained from Sage Therapeutic's financial statements, Sage Therapeutic may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Sage Therapeutic's ability to earn profits and add value for shareholders. As of December 20, 2024, Price To Sales Ratio is expected to decline to 14.25. In addition to that, Days Sales Outstanding is expected to decline to 338.54. At present, Sage Therapeutic's Net Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Income is expected to grow to about 37.9 M, whereas Operating Income is projected to grow to (550.9 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin1.050.975
Significantly Up
Pretty Stable
For Sage Therapeutic profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sage Therapeutic to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sage Therapeutic utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sage Therapeutic's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sage Therapeutic over time as well as its relative position and ranking within its peers.
  

Sage Therapeutic's Revenue Breakdown by Earning Segment

Check out World Market Map.
For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sage Therapeutic. If investors know Sage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sage Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.57)
Revenue Per Share
1.76
Quarterly Revenue Growth
3.371
Return On Assets
(0.30)
Return On Equity
(0.49)
The market value of Sage Therapeutic is measured differently than its book value, which is the value of Sage that is recorded on the company's balance sheet. Investors also form their own opinion of Sage Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Sage Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sage Therapeutic's market value can be influenced by many factors that don't directly affect Sage Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sage Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sage Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sage Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Sage Therapeutic Revenue vs. Shares Owned By Insiders Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Sage Therapeutic's current stock value. Our valuation model uses many indicators to compare Sage Therapeutic value to that of its competitors to determine the firm's financial worth.
Sage Therapeutic is rated below average in shares owned by insiders category among its peers. It also is rated below average in revenue category among its peers totaling about  7,259,026  of Revenue per Shares Owned By Insiders. At present, Sage Therapeutic's Total Revenue is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Sage Therapeutic by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Sage Revenue vs. Shares Owned By Insiders

Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Sage Therapeutic

Insiders Shares

 = 

Executives Shares

+

Employees

 = 
11.91 %
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Sage Therapeutic

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
86.45 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Sage Revenue vs Competition

Sage Therapeutic is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 7.07 Billion. Sage Therapeutic claims roughly 86.45 Million in revenue contributing just under 2% to equities under Health Care industry.

Sage Therapeutic Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Sage Therapeutic, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sage Therapeutic will eventually generate negative long term returns. The profitability progress is the general direction of Sage Therapeutic's change in net profit over the period of time. It can combine multiple indicators of Sage Therapeutic, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-814 K-854.7 K
Operating Income-579.8 M-550.9 M
Income Before Tax-541.5 M-514.4 M
Total Other Income Expense Net38.4 M40.3 M
Net Loss-541.5 M-514.4 M
Income Tax Expense-5.4 M-5.6 M
Net Loss-655.9 M-623.1 M
Non Operating Income Net Other17.2 K16.4 K
Net Loss-479.5 M-455.5 M
Net Interest Income36.1 M37.9 M
Interest Income36.1 M37.9 M
Change To Netincome69.1 M70.3 M
Net Loss(9.05)(9.50)
Income Quality 1.00  0.68 
Net Income Per E B T 1.09  1.06 

Sage Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Sage Therapeutic. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sage Therapeutic position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sage Therapeutic's important profitability drivers and their relationship over time.

Use Sage Therapeutic in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sage Therapeutic position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sage Therapeutic will appreciate offsetting losses from the drop in the long position's value.

Sage Therapeutic Pair Trading

Sage Therapeutic Pair Trading Analysis

The ability to find closely correlated positions to Sage Therapeutic could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sage Therapeutic when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sage Therapeutic - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sage Therapeutic to buy it.
The correlation of Sage Therapeutic is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sage Therapeutic moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sage Therapeutic moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sage Therapeutic can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Sage Therapeutic position

In addition to having Sage Therapeutic in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Consumer Staples ETFs Thematic Idea Now

Consumer Staples ETFs
Consumer Staples ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Consumer Staples ETFs theme has 13 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Staples ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Sage Therapeutic is a strong investment it is important to analyze Sage Therapeutic's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sage Therapeutic's future performance. For an informed investment choice regarding Sage Stock, refer to the following important reports:
Check out World Market Map.
For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.
You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
To fully project Sage Therapeutic's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Sage Therapeutic at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Sage Therapeutic's income statement, its balance sheet, and the statement of cash flows.
Potential Sage Therapeutic investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Sage Therapeutic investors may work on each financial statement separately, they are all related. The changes in Sage Therapeutic's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Sage Therapeutic's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.